The interaction of adriamycin with small unilamellar vesicle liposomes. A fluorescence study
- PMID: 583025
- DOI: 10.1016/0005-2736(79)90329-8
The interaction of adriamycin with small unilamellar vesicle liposomes. A fluorescence study
Abstract
The interaction of the antineoplastic agent adriamycin with sonicated liposomes composed of phosphatidylcholine alone and with small amounts (1-6%) of cardiolipin has been studied by fluorescence techniques. Equilibrium binding data show that the presence of cardiolipin increases the amount of drug bound to liposomes when the bilayer is below its phase transition temperature and when the ionic strength is relatively low (0.01 M). At higher ionic strength (0.15 M) and above the Tm (i.e. conditions which are closer to the physiological state) the binding of the drug to the two liposome types is nearly the same. Thus the differences in the interactions of adriamycin with cardiolipin-containing membranes, as opposed to those composed of phosphatidylcholine alone, are not due simply to increased binding but rather to an altered membrane structure when this lipid is present. Quenching of adriamycin fluorescence by iodide shows that bound drug is partially, but not completely, buried in the liposomal membrane. Both in the presence and absence of cardiolipin the bulk of the adriamycin is more accessible to the quencher below the Tm than above it; that is, a solid membrane tends to exclude the drug from deep penetration. Above the Tm, the presence of cardiolipin alters the nature of liposome-adriamycin interaction. Here the fluorescence quenching data suggest that the presence of small amounts of cardiolipin (3%) in a phosphatidylcholine matrix creates two types of binding environments for drug, one relatively exposed and the other more deeply buried in the membrane. The temperature dependence of the adriamycin fluorescence and the liposome light scattering reveal that cardiolipin alters the thermal properties of the bilayer as well as its interaction with adriamycin. At low ionic strength lateral phase separations may occur with both pure phosphatidylcholine and when 3% cardiolipin is present; under these conditions the bound adriamycin exists in two kinds of environment. It is notable that only adriamycin fluorescence reveals this phenomenon; thebulk property of liposome light scattering reports only on the overall membrane phase change. These data suggest that under certain conditions the drug binding sites in the membranes are decoupled from the bulk of the lipid bilayer.
Similar articles
-
Effects of adriamycin on lipid polymorphism in cardiolipin-containing model and mitochondrial membranes.Biochim Biophys Acta. 1985 Sep 25;819(1):55-65. doi: 10.1016/0005-2736(85)90195-6. Biochim Biophys Acta. 1985. PMID: 4041451
-
On the reversal by deoxyribonucleic acid of the binding of adriamycin to cardiolipin-containing liposomes.J Biol Chem. 1993 Jan 15;268(2):1074-80. J Biol Chem. 1993. PMID: 7678246
-
Interaction of Ca2+ with cardiolipin-containing liposomes and its inhibition by adriamycin.Biochem Pharmacol. 1985 Dec 15;34(24):4291-8. doi: 10.1016/0006-2952(85)90287-4. Biochem Pharmacol. 1985. PMID: 4074389
-
Factors influencing the distribution pattern of porphyrins in cell membranes.J Photochem Photobiol B. 1990 Jun;6(1-2):69-77. doi: 10.1016/1011-1344(90)85075-8. J Photochem Photobiol B. 1990. PMID: 2121940 Review.
-
Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity.Biophys Chem. 1990 Apr;35(2-3):247-57. doi: 10.1016/0301-4622(90)80012-v. Biophys Chem. 1990. PMID: 2204444 Review.
Cited by
-
Characterization of cellular lipids in doxorubicin-sensitive and -resistant P388 mouse leukemia cells.Cancer Chemother Pharmacol. 1986;17(1):11-5. doi: 10.1007/BF00299859. Cancer Chemother Pharmacol. 1986. PMID: 3698172
-
Physical entrapment of adriamycin in AB block copolymer micelles.Pharm Res. 1995 Feb;12(2):192-5. doi: 10.1023/a:1016266523505. Pharm Res. 1995. PMID: 7784332
-
Binding of adriamycin to liposomes as a probe for membrane lateral organization.Biophys J. 1999 Feb;76(2):896-907. doi: 10.1016/S0006-3495(99)77253-X. Biophys J. 1999. PMID: 9929491 Free PMC article.
-
Doxorubicin Inhibits Phosphatidylserine Decarboxylase and Modifies Mitochondrial Membrane Composition in HeLa Cells.Int J Mol Sci. 2020 Feb 15;21(4):1317. doi: 10.3390/ijms21041317. Int J Mol Sci. 2020. PMID: 32075281 Free PMC article.
-
Adriamycin inhibits PTH-mediated but not PGE2-mediated stimulation of cyclic AMP formation in isolated bone cells.Calcif Tissue Int. 1984 May;36(3):279-84. doi: 10.1007/BF02405331. Calcif Tissue Int. 1984. PMID: 6088009
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources